Nature S Sunshine Products Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Nature S Sunshine Products Inc in the second quarter 2026?
Nature s Sunshine Products inc achieved a return on average equity (ROE) of 11.26 % in its second quarter 2026, this is above NATR's average return on equity of 8.46%.
Nature S Sunshine Products Inc shareholder's equity over the 12 months ending in its second quarter 2026 are valued at $166 million

ROE decreased relative to the period ending , due to the decline in net income.

Within the Major Pharmaceutical Preparations industry 49 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 1138 to 1149.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	3.44 %	-0.11 %	0.35 %	2.51 %	-
Y / Y Net Income Change	-35.89 %	4.79 %	-	19.13 %	270.9 %
Net Income (TTM) in Millions	19	21	20	15	14
Return On Equity (TTM)	11.26 %	12.56 %	12.41 %	9.24 %	8.75 %
NATR's Total Ranking	# 1149	# 1138	# 885	# 984	# 1339
Equity (TTM) in Millions	169	167	162	167	164
Seq. Equity Change	1.44 %	3.32 %	-3.09 %	1.85 %	-2.05 %
Seq. Net Income Change	-30.87 %	13.41 %	-18.46 %	0.29 %	13 %

Back to NATR Management Effectiveness >> NATR's 5 Years Annual ROE >> Compare NATR ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 50
Sector	# 130
Overall	# 1149

Return On Equity Statistics
High	Average	Low
28.67 %	8.46 %	-13.17 %
(Sep 30 2012)		(Sep 30 2018)

NATR Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	162	161	160	147	161
Y / Y Equity Change	0.35 %	0.91 %	8.5 %	-8.9 %	2.65 %
Net Income in Millions	20	8	16	1	30
Y / Y Net Income Change	159.14 %	-51.92 %	2884.73 %	-98.18 %	31.58 %
Return On Equity	12.66 %	4.9 %	10.29 %	0.37 %	18.72 %

Back to NATR Management Effectiveness >> NATR's 5 Years Annual ROE >> Compare NATR ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 12.66 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
NATR's' Return on Equity at Yahoo Finance
NATR's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for NATR's Competitors
Subscribers only: Roe for Nature S Sunshine Products Inc 's Suppliers
Subscribers only: Return On Equity for NATR's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Innoviva Inc	30.03 %
Phibro Animal Health Corporation	29.66 %
Chemed Corporation	29.45 %
Solventum Corporation	28.96 %
Pacs Group Inc	27.00 %
Sotera Health Company	26.75 %
Insulet Corporation	26.69 %
Bioventus Inc	25.96 %
Johnson and Johnson	25.74 %
Encompass Health Corporation	25.52 %
Resmed Inc	24.21 %
Healthcare Services Group Inc	24.12 %
Electromed Inc	23.65 %
Iradimed Corporation	23.45 %
Vertex Pharmaceuticals Inc	23.31 %
Lantheus Holdings Inc	23.27 %
Msa Safety Inc	23.15 %
Prestige Consumer Healthcare Inc	21.77 %
Jazz Pharmaceuticals Plc	21.37 %
Neurocrine Biosciences Inc	21.13 %
Universal Health Services Inc	20.89 %
Puma Biotechnology Inc	20.85 %
Entera Bio Ltd	20.82 %
United Therapeutics Corporation	20.18 %
Ligand Pharmaceuticals Incorporated	20.06 %
Harmony Biosciences Holdings inc	20.06 %
Pediatrix Medical Group Inc	19.89 %
Theravance Biopharma inc	19.40 %
Krystal Biotech Inc	19.34 %
Ani Pharmaceuticals Inc	19.33 %

Date modified: 2026-09-26T07:14:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.